Replies to post #208872 on Biotech Values

[DewDiligence]

AGN 4Q16 CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNDYzNjh8Q2hpbGRJRD02NTk2NTM=

[DewDiligence]

1Q17 worldwide Botox sales=$714M, +12% YoY (-3% QoQ*):

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNTMzMDR8Q2hpbGRJRD02NzAzMjY=

• US therapeutic†: $325.6M (+13% YoY)
• US cosmetic: $183.8M (+11% YoY)
• Ex-US therapeutic: $82.4M (+7% YoY)
• Ex-US cosmetic $122.2M (+18% YoY)

In other words, 71% of Botox sales were in the US, where the therapeutic†/cosmetic split was 64/36; 29% of Botox sales were ex-US, where the therapeutic/cosmetic split was 40/60.

*The sequential QoQ decline was expected; for cosmetic indications, the second and fourth quarters are seasonally stronger than the first and third quarters.

†Includes hyperhidrosis.